15q11.2...............T167
1H MRS...............T128, W113, W177
1NMPP1...............W160
22q11...............32, W32
31P Magnetic Resonance Spectroscopy...............W188
5-HT2A receptor...............W166
5F-PB-22...............T250
6-OHDA...............W138
7-Tesla...............W101
7q11.23...............W28
[11C]DPA-713...............T140
A
Abuse Potential...............4, T208, T249
accelerometry, mood disorders, big data...............W105
acetylcholine...............M4, M130, W64
acoustic startle...............M171, T78, W17
Actigraphy...............M114, W105
Acute Stress...............M104, T247, T253, W97
Adaptive Behavior...............T136
addiction...............5, M222, M223, M224, M228, M233, M257, 14, 19, T51, T53, T171, T210, T212, T215, T216, T219, T242, T249, 28, 43, W126, W217, W242, W261, 51, 55
adenosine...............31
ADHD...............T31, W26, W29, W34
adherence...............M153
adjunctive treatment...............T82
Adjuvant thiamine...............M81
Adolescence...............M24, M27, M28, M162, M257, T26, 31 T94, T171, T210, T244, T260, W31
Adolescent...............M26, M67
Adolescent Alcohol...............W237
Adolescent binge drinking...............44
Adolescent Depression...............M30, T35, T102, W38
Adolescent Development...............T21
Adolescent Stress...............M33, T21
Adolescents...............T39, W37, W40
adult neurogenesis...............M99, T241
advantages of the combination of therapies...............T134
affective disorders...............M130
African American...............W109
aggression...............T52, T149, W51
Aging...............M4, M146, M147, M151, T3, T4, T113, W2, W233
aging and dementia...............W3
Agitation...............M187
AKT1/AKT3...............W151
Alcohol...............M28, M215, M222, M247, T211, T224, T261, W221, W235, W239
alcohol and drugs...............60
Alcohol consumption...............T42, W258
Alcohol dependence...............M227, M241, M253, M259, T231, W209, W245, W255
alcohol self-administration...............M245, M256, W255
Alcohol Sensitivity...............T262
alcohol use disorder...............M219, T211, T220, T222, W253
Alcohol withdrawal syndrome...............W220
Alcohol-preferring rats...............W220, W236
Alcohol-seeking...............W236
Alcohol-seeking behavior...............T238, W142
Alcoholism...............M251, M256, M263, 11, 52
alic...............W136
all is in the timing...............T134
allopregnanolone...............T78
alpha 5...............T212, W238
alpha-7 nicotinic acetylcholine receptor...............M25, T206, T207
Altitude...............T97, T236
Alzheimer's Disease...............M41, M43, 16, M145, T2, T43, T44, T141, W1, W4, W41, W42, W43
Ambiguity...............T217
Amino acid mixture...............T72
Amish...............25
AMPA...............W95
AMPA antagonist...............M142
AMPA glutamate receptors...............W221
AMPA receptor...............M77, M186
Amphetamine...............M180, M260
amplitude of low frequency fluctuation...............M163
Amygdala...............M6, M14, M78, M97, M131, M211, T14, T16, T28, T35, T90, T172, W25, W144, W237
amygdala-based networks...............T26
Amyloid...............T2
Amyloid Precursor Protein...............W41
anatomical connectivity...............W134
anesthesia...............M121
Anesthetic...............T54, W137
Anger...............M107
anhedonia...............T254, W37, W106, W108, W232
Animal Model...............9, M57, T8, T85, T160, T181, T190
Animal Models...............M76, M157, M263, 18, T65, T70, T91, W79, W146
ankyrin-3...............M99
anorexia nervosa...............M49, T47, W47, W48
anterior cingulate cortex...............T2, T101, T130, W51, W60, W84, W122, W163
anterior prefrontal cortex...............T192
anti-ADHD like action...............W35
Antidepressant...............4, M35, M62, M77, M83, M167, T35, T91, T102, T109, T112, W66, W78, W87, W113, W114
antidepressant response...............M85, T85
Antidepressants...............M59, T56, T58, T61, T81, T101, W70, W97, W111
Antipsychotic...............M157, M159, M167, T201, W39, W168, W174
Antipsychotic agents...............T150
Antipsychotic induced weight gain...............M177, W39
antipsychotic medication...............W206
Antipsychotic monotherapy...............M206
Antipsychotic switching...............M193
Antipsychotic Treatment...............M168, M170, M190, M191, W184
antipsychotic-naive...............W152
Antipsychotic-naïve first-episode schizophrenia...............M190, 12
Antipsychotics...............T157, T174, T181, W132, W156
antisocial personality disorder...............M148, M150
Anxiety...............M15, M31, M88, T13, T14, T17, T59, T63, T67, T120, T148, W6, W8, W10, W15, W20, W81, W87, W94, W126, W144, W237, 52, 55
Anxiety disorders...............M9, M12, M20, T16, 30, 41, W16, W22, 6
anxiety state...............T9
anxiolytic...............W87
Anxious distress...............M88
apathy...............W73
Appetite...............T121
Appetitive Hormones...............5, T137
Arc...............W250
Arcuate...............M126
aripiprazole once-monthly 400 mg (AOM 400)...............T187, W154
ASD...............M8
aspirin...............T76
associative learning...............M213, W251
associative-striatum...............W177
ASSR...............M160, W186
astrocytes...............M133
astroglia...............54
at-risk...............M199, T15, W17
Attention...............M136, M162, M226, T7, T111, T129, T130, T255, W117
Attention Deficit Hyperactivity Disorder...............T53
attentional bias...............M98, T59
attentional bias modification...............W229
atypical antipsychotic drug...............M56, T62, W172
Atypical antipsychotics...............M34, M55, M65, M186, T79, T114, T185, W56
Auditory cortex...............M197
Auditory hallucinations...............T166, W202
augmentation...............M65
Autism...............T25, M38, T34, T132, T142, W27
Autism & depression...............57
Autism spectrum disorder...............M128, M241, W43, W91, W166
autism Spectrum Disorders...............M37, M44, M36, T33, T37, T144, W30, W204
B
Balb/c mouse...............M36
Basal Ganglia...............M232, T105
basolateral amygdala...............M119, M255
bath salts...............M250
BB-22...............T250
BDNF...............M62, M67, M111, M202, T74, T95, T188
Behavior...............M242, 37, 55
behavioral despair...............T68
behavioral economics...............T242
behavioral inhibition...............T53, W25, W142
Behavioral Pharmacology...............M231, T218, T237, W41, W50
behavioral variability...............W26
Behaviors...............M140
benign neutropenia...............M172
benzodiazepine...............M167, W114
beta arrestin...............M165, M169, M261, 53
beta-amyloid peptide 1-42...............T42
big data...............T96
binge drinking...............M263, T211, T218
binge-eating...............T46, W49
Binge-eating disorder...............W46, M47, M48, M223
Bioenergetics...............M199
Bioinformatics...............T144
Biomarker...............M41, M58, M111, T27, T76, T95, T141, W66, W100, W159
Biomarker risk assignment algorithm...............M108
biomarkers...............T8
bipolar...............M199
bipolar depression...............T77
Bipolar Disorder...............M55, M67, M82, M91, M93, M101, M110, M112, M114, M115, M147, M153, M188, T64, T163, T71, T76, T96, T104, T108, T111, T119, T194, W63, W71, W77, W79, W82, W88, W89, W99, W202
Bipolar I Depression...............T62, W56
BNST...............M14, T120
Body Dysmorphic Disorder...............M21
BOLD imaging...............M236, T12
Borderline Personality Disorder...............M149, T146, W147, W148, 47
Brain...............T56, T136
brain activation...............38
Brain Anatomy...............T130
Brain Based Markers for Depression...............M90, M98
brain connectivity...............M1, T32
Brain development...............M35, M50, T41, W25, W181
brain hemispheres...............T134
brain imaging...............30, 52
Brain Stimulation...............T77, 43, W102, W103, W112, W121
brain structure...............W124, W141, W181, W219
brain volume...............T74
brain volumes...............T200, W21
Brain waste removal...............16
Brain-Derived Neurotrophic Factor...............M174
breast cancer...............M139
Brexpiprazole...............M88, M107, M187, M193, T88
bulimia nervosa...............M50
Buprenorphine...............T228, T232, W72
buprenorphine maintenance...............M258
bupropion...............T80
C
c-Fos...............M99, M212
CACNA1C...............T3, T119
caffeine...............M250, T248, 31, W208
calcium...............T119
calcium imaging...............M213, T16, W131, W211, 55
Cannabidiol...............W225, W259
cannabinoids...............M217, M221, T250, 28
cannabis...............M15, 19, T210, T234
Cannabis Dependence...............M154, M247, M262, T168, T256, W227, W241, W260
cannabis use...............T171, T173, T175, T260, W216
CANTAB...............M41
Cardiac Reactivity...............T262
Cardiometabolic Risk...............W39, W132, W190
Career Development...............M124
cariprazine...............M156, M204, M206, T170
catenin cadherin-associated protein, alpha 2,...............M53
CB1 receptor...............T250, W227
CBT...............M18, T22
CCK-4...............M16
Central autonomic network...............M80, W121
Central nucleus of the amygdala...............W59, W221
Cerebral Blood Flow...............M49, W235
Child abuse and neglect...............T39, W233
child offspring...............T104
childhood maltreatment...............M39
Childhood Onset Bipolar Disorder...............23
Childhood trauma...............M26, M210, W145
childhood urban-rural upbring...............W207
Children and Adolescents...............T27, T98, W39
choice...............M216, T252
choline...............M25, T157, T206
cholinergic system...............W43, W64
chromatin...............W27, W139
chronic...............T190
chronic mild stress...............T73, W72
chronic pain...............W86, W143, W230
chronic social defeat...............M96
chronic stress...............M104, T60, T138, W50, W75, W110, W240
cingulate...............T86
circadian...............W239
circadian rhythm...............M12, M111, M139, M147, T258
citalopram...............T80
cladistics...............W158
CLARITY...............W194
Clathrin nanoparticles...............W128
claustrum...............T130, T182
clinical high risk...............T155, T161, T172
Clinical trial...............M83, W129, W169, M86, M128, M241, T195, W43, W91, W166
Clinical Trial Design...............W57
Clinical Trial Methodology...............15, 24
CLOCK...............T258
clomipramine...............W122
clonidine...............M258
Clozapine...............M172, T185, M191, T203, W175, W203
Cluster Analysis...............T204
CNS antibody delivery...............W128
CNS Clinical Trials...............M253, T222
CNV...............T25, W32
co-abuse...............M263, T261
Cocaine...............M213, M214, M220, M222, M231, M233, M243, M250, T183, T216, T219, T229, T233, T235, T253, T261, W210, W217, W228, W242, W243, W250
cocaine addiction...............M223, M225, M236, M237, M239, M240, M248, M252, T251, T252, T254, T258, T259, 28, W35, W212, W214, W219, W222, W246, W247, W254
cocaine seeking...............M211, M255, W222, W231, W240, 54
cocaine-related disorders...............M220
Cognition...............M4, M41, M45, M72, M112, M120, M154, M179, M181, M192, T3, T82, T98, T105, T111, T159, T162, T186, T191, T204, T234, T244, W4, W89, W119, W155, W162, W165, W171
cognitive aging...............M1, M3, T2
cognitive behavior therapy...............M26, M100
cognitive behavioral therapy...............M23, M95
cognitive control...............M90, T117, T173, W23, W51, W226
cognitive control network...............M95
Cognitive Decline...............T87, T113
cognitive deficit...............T196
Cognitive Enhancement...............M28, M130, T24, W125
Cognitive Functioning...............T93
Cognitive impairments...............W188
Cognitive Neuroscience...............M26, 17, T209, 51
cognitive reappraisal...............M149
cognitive remediation...............M166, T152, T164, W205
Cognitive Resilience...............T54, W1
cognitive training...............17
cognitive/emotional task performance...............W116
combat...............T15
combat veteran...............M17, W21
community based family study...............T108
community structure...............T122
compensatory cognitive training...............T151
compulsion...............W9
Compulsive eating...............T49
compulsivity...............M51, M52, M248, 14
computational modeling...............T51, W127
COMT gene...............W145
concerns...............60
conditioned cue...............W7, W142
conditioned place preference...............T229, T236, W211, W249
Conditioned responses...............W120
conflict of interest...............35
Connectivity...............M224, T18, T117, W76, W165, W191
Connectivity strength...............T90
connectome...............T75, W55, W134
connectomics...............T122, W192
consciousness...............T134
Context...............T225, W7
coping...............M23
copy number variation...............M37, 25
cortex...............M137, W130
cortical dynamics...............W192
Cortical Inhibition...............T27, T168, W112
Cortical neurons...............T238
cortical thickness...............W36
cortico-striatal plasticity...............M234
corticoaccumbens circuit...............W49
corticosterone...............M61, T23, W94
Corticotropin-releasing factor (CRF)...............W214
Corticotropin-Releasing Hormone...............M76
Cortisol...............M10, M14, M109, M139, T84, T86
COX-1...............M54
CpG Methylation...............M9
CR845...............M129
craving...............T137, T230, T256
CREB...............T42, T115
CRF...............T233, W5
CRH...............T67, W22, W115
CRHBP...............W14
CRP...............M120, T100
CSF...............M94
CSF Biomarkers...............T87
Cue Reactivity...............W218
cue reinstatement...............M221, M225, W225
Cue-Exposure...............T226, T230
cue-reactivity...............W248
cues...............W212
Cyberball...............T228
cyclic AMP...............W66
CYP2C19...............M59
cytokines...............M13, M94, M117, 21, T100, T105, W61, W107, W135, W204
Cytoprotection...............M143
cytoskeleton...............T57
D
D-amino acid oxidase...............W199
D-serine...............M214
D2 receptor...............M169, W107, W151, W166, 53
Data sharing...............15
Data transparency...............15
DBS...............T46, W9, 56, 59
de novo...............M37
de novo mutation...............M174, M201, W33
Decision Making...............M131, M202, M215, T13, T51, T217
declarative memory...............M7
deep brain stimulation...............M38, M90, W100, W209
default mode network...............M60, M141, T101, W11, W101
default network...............T180
delay discounting...............13
delta9-tetrahydrocannabinol...............W225
Delusions...............T192
Dementia...............T145
dendrites...............M196, W181
Dendritic Spine...............1, M161, M233, T102
dentate gyrus...............T19
depot...............M153
Depression...............4, M15, M57, M60, M61, M69, M72, M75, M84, M87, M91, M96, M98, M102, M113, M118, M121, M140, T10, T56, T63, T68, T70, T73, T77, T86, T91, T92, T97, T99, T101, T184 38, 40, W58, W63, W64, W65, W70, W74, W76, W80, W87, W90, W91, W97, W98, W107, W110, W123, 52, 56, 59
depressive disorders...............M85
Design...............8
development...............T4, T131, T202, T234, 38
Developmental...............T181, W20
Developmental Psychopathology...............M45, 20
developmental trajectories...............M34, 24
Dextromethorphan/Quinidine...............M145, T145
diabetes...............T139
diagnostic criteria...............51
diagnostic specificity...............W158
Dietary supplement...............T116
diffusion...............M106
Diffusion tensor imaging...............T32, W194
Diffusion Weighted Imaging...............M60, T205, T219
Digital Health Feedback System...............M200
dimensions of psychosis...............W192
diphtheria toxin...............W187
Direct pathway...............M137
DISC1...............M228, W149, W193
Disease prevalence...............M143
disease progression...............M139
disparities...............M2
disruptive mood dysregulation disorder...............T29
divergent transcription...............T188
DKI...............M106
DLPFC...............M196, T144, W165
DNA Methylation...............M197, W213
DNA sequencing...............T163
domesticate...............W146
Dopamine...............M28, M79, M165, M168, M176, M177, M178, M179, T192, M198, M212, M215, M217, M218, M226, M238, M248, M262, T31, T73, T135, T180, T207, T212, T227, T254, T258, W45, W69, W98, W106, W115, W171, W174, W181, W212, W217, W218, W257, W261, W262, 53
Dopamine (D2, D3) receptors...............M159, M175, M176, M177, M216, T239, W244, W247
dopamine 2 receptor...............W170
Dopamine 3 receptor imaging...............W128
dopamine d4...............W203
dopamine transporter...............M232, T31, W73, W123, 57
Dopaminergic system...............T67, W58
Dopmaine...............T136
Dopmaine Receptors...............M48
dorsal caudate...............T150, W177
Dorsal striatum...............M137, M248, W69
dorsolateral prefrontal cortex...............M42, M152, W84, W122
dorsolateral striatum...............M211
Dose-response Analyses...............M55
Down Syndrome...............W140
downregulation...............W227
DRD2 locus...............T174, W151
DREADD...............M42, T218, T233, W15, W49
DREADD Receptor...............T214
DREADDs...............M23, T235
drinking...............W215
drug abuse...............T252
Drug Discovery - new approaches...............50
drug discrimination...............M250
DTI...............M40, T176, W119
duloxetine...............W86
Dup7...............W28
Dynorphin...............T218
E
Early intervention...............6, W149
Early life stress...............M32, M39, M87, T39, T110, T139, W69
Early Phase Drug Development...............W253
early psychosis...............W206
early sensory signal processing...............T24
early signs...............45
Eating disorder...............5
Eating Disorders...............M47, T48, W46, 36
ecological momentary assessment...............M258
ECT...............W76, W103
Editorial...............8
education...............T133
EEAT2...............T64
EEG...............M121, M164, M184, T155, W103, W193, W208
EEG biomarkers...............T146, T230, W68
Effort...............W157
Electroconvulsive therapy...............M38, M68, T77, T107, T203, W55, W68, W90, W112
electroencephalography...............M160
Electronic cigarette (e-cigarette)...............M242
electrophysiology...............M131, M169, M186, T43, T88, T130, T142, T255, 37, W83
emergence...............M121
emotion...............T86
Emotion Modulation...............T7
Emotion Perception...............W12
Emotion processing...............M66, M78, T12, T71, T228, W116
emotion regulation...............M32, T12, T164
emotional response inhibition...............M152, T71
Emotional stress...............M57
Emotional Test Battery...............M72
endocannabinoid...............M15, T110
Endocannabinoids...............W94, W147
Endomicroscopy...............W211
endophenotype...............T25, M112, M171, 13, T36, T84, 39
endophenotypes...............T45, T96, T108
endurance training...............M166
energy homeostasis...............M49
epidemiology...............M45, T5, T231
Epigenetic...............3, 11, T144, W52, W243, 49
Epigenetics...............M9, M35, M39, M214, T60, T64, T165, T201, W41, W96, W140, W213, W254
epilepsy...............M142, M144
episodic memory...............41, W197, W207
ErbB4...............W160
ERP...............2, M184, T156, T230, W198
ERPs...............M160, W117
Escitalopram...............M21, T80
Esketamine...............M62, T91, T93, T106, W57
eSource...............W150
Estradiol...............M3, M4, M113, T118
estrogen...............T66
estrogen receptor...............T11
ethanol...............M251, W31
ethics...............35
evoked response potential...............M173
Excitabilty...............M243, W102
executive function...............M67, M90, M135, M224, T2
exercise...............W133, W246
exome...............W148
exome sequencing...............M37
Exposure therapy...............M10, M18
extended reward network...............W134
Extinction learning...............M245, 6
Extinction memory recall...............W118
extracellular matrix...............T251
extrastriatal dopamine D2/3 receptors...............W152
F
FAAH...............T256, W14
FAAH inhibitor...............T256
face perception...............M173
face specific processing...............M173
factor analysis...............W99
familial risk...............T5
familiarity...............T193
Fast-acting Antidepressant...............M111, T65, T70, W58, W96
fatty acids...............27, M118
fear...............T14, W146
Fear conditioning...............M6, M13, M20, M138, T6, T22, T172, W5, W13, W17, W20
Fear extinction...............M138, T6, T19, T22, W7, W9, W13, W17
fear generalization...............10, 41
fear processing...............41
FEAST...............W103
Feedback negativity...............T156
Female...............M57
Field trial...............M101
first episode schizophrenia...............M163, T173, W184, W205
First-episode psychosis...............T205, W168, W177, W197
first-episode schizophrenia...............T149, T155
FKBP5...............M39, W74
flibanserin...............T208
Fluorescence-activated cell sorting...............T182
fMRI...............2, M1, M3, M91, M98, M122, M132, M173, M224, M226, M246, M249, 17, T7, T17, T59, T117, T121, T125, T127, T128, T137, T172, T173, T257, W26, W37, W38, W47, W65, W102, W116, W118, W120, W137, W144, W157, W165, W235, W248
fMRI faces paradigm...............T52
fMRI Functional Connectivity...............M19, M80, M95, T180, W133, W222
fMRI resting state...............M163, W10, W76
fMRI, anxiety, threat...............W23
fMRI/imaging genetics...............19, T159, W1, W34, W218
FMRP...............T167
fNIR...............2, W232
Food Addiction...............W46, W244
forced swim test...............T97, W97
Fractional-anisotropy...............M106, T219, T240
fronto-striatal networks...............W151
Functional Capacity...............M170, T139
Functional connectivity...............T69, T216, W179
functional impairment...............W88
functional magnetic resonance imaging...............T66, W180, W207
functional neuroimaging...............M7, M203, 21, T166, W106, W216
functional outcome...............W189
Functional Selectivity...............M165, M176, M261, W170
Funding...............M124
FXR1P...............M66
G
g protein signaling...............M261, 27
G-protein...............W66
GABA...............M74, M84, M178, T247
GABAA...............T78, W149, W173
GABAB...............M259
GABAergic cells...............W187
GABAergic circuitry...............W155
GABAergic interneurons...............M31, T153, W183, W262
Gabapentin...............W53
GAD65/67 mRNA...............M48
gait...............T25
Galanin...............W258
gamma oscillation...............T155, W185, W186
gender...............M148, T90, T243, W38
Gene environment interaction...............M228
gene expression...............11, T8, T10, T178, T182, T229, 42, W48, W70, W84, W143, W239, 49
generalized anxiety disorder...............W12
genes...............48
genetic...............M43, M183, 13, W79, W115
genetic mouse model...............7, T25, T57, T229, 32, W239
genetics...............M120, M130, M171, M174, M219, M259, 25, T127, T132, T157, 39, W78, W111, 48
Gene–environment interaction...............T48, W207
genome editing...............M229
Genomics...............M123, 34
geography and drug addiction...............T236
Geometry...............T148
Global Deterioation Scale...............T1
Global outreach...............26
GLT-1...............M243, T253, W220
glucocorticoid...............M94, T246
glucocorticoid receptor...............M255, W74, W97
Glutamate...............M16, M30, M51, M86, M125, M175, M178, M222, M262, T64, T104, T127, T161, T178, T206, T207, T213, W96, W177, W220, W249, 29
glutamate GABA...............M198, T43, T177, W44
glutamate receptor activity...............M197
glutamate transport...............T198
glutamate/glutamine cycle...............M30
glutamatergic synapses...............W204
glutamatergic transmission...............W8
Glutamine...............M30
glutathione...............M22
glycogen synthase kinase-3...............W95
glycosylation...............M207
Glymphatic pathway...............16
Gonadal Hormones...............M105, T118, 36
GPCR...............M79, 50
GPHN...............W14
Graph theory...............T99, W68
GSK3...............M66
guanfacine...............M97
guanylyl cyclase...............M205
Gut Microbiome...............T40, T63, W126, W141
GWAS...............M93, M181, 13, 22, W21, W78
gyrification...............W28
H
habit...............M248, 22, T213
hallucinogen...............W124, W178, 52
haloperidol...............T178
harm avoidance...............M8, T47
Harm reduction...............W259
hbA1c...............T139
HDAC...............T179
HDAC inhibitors...............W41
head-to-head clinical trial...............T187, W154
health-related quality of life...............T187, W154
healthy individuals...............W122
Heart Rate Variability...............M80, T15, T262
Heroin...............M254
heterogeneity...............W99
heterogenity...............W77
high fat diet...............33
high risk...............12
high risk psychosis...............M27, W182, W189
Hippocampal Function...............W1
Hippocampus...............M11, M64, M182, T19, T57, T109, T110, T148, T178, T225, T235, T241, W107, W145, W211
hIPSCs...............32
Histamine...............W30
Histone...............T144, W96, W140
Histone methylation...............W237
HIV...............M75, T138
HIV-1...............W73
HMGB1...............M64
Hoarding Disorder...............W24
homer...............W249
Hostility...............M187
Hot Flashes...............M113
HPA axis...............M10, M39, M210, T224, W31
Hsp90...............W74
HTR3B...............W14
hub analysis...............T122
Human Factors Testing...............M200
human laboratory...............M216, M239, T222
Human Neuroimaging...............M50, M134, M216, M236, M254, 17, 19, T18, T89, T138, T143, T244, W18, W21, W23, W124, 44, 47, 51
humans...............T8, T72
hunger...............M49
Huntington's Disease...............W139
hypersexual disorder...............M210
Hypothalamic development...............M126
Hypothalamic-Pituitary-Adrenal axis...............T21, T23, T84
hypothalamus...............M105, T16
Hypoxia...............T236
I
ibudilast...............W253
imaging...............M249, M257, T142, T227
imaging genetics...............T26, W42
Immune...............M183, M188
immune mechanisms...............33, W153
impulsiveness...............T89
impulsivity...............M46, M51, M52, M53, M99, 13, T31, T53, T239, W49, W209, W245, 44
in vitro cellular model...............T167
In vivo Imaging...............1
inbred mouse strains...............T124
Incentive motivation...............M218, W258
incentive salience...............W251
inclusion and exclusion...............W216
incubation...............W240
individual differences...............M135, M252, T6, T125, W25, W126, W210, W251
Induced pluripotent stem cells (iPSCs)...............T119, T167, W48, W130, 48
infant...............M25, W25
infertility...............W16
inflammation...............M13, M64, M118, M120, M133, 21, T105, T160, 27, W89, W106
Inflammatory Markers...............M54, W61
informatics...............T75
infralimbic cortex...............T73, T213, W245
Inhibition...............T61, W145
Inhibitory control...............M260, T216, W50
inhibitory synaptic transmission...............W183
innovative methods...............W169
Insula...............T215, T243, W47, W179, W241
Insula Connectivity...............W85
Insulin...............M177, W8
insulin resistance...............M85, T83
Insulin-like growth factor 1...............T37
intellectual disability...............W27
Intelligence Quotient...............W119
interleaved TMS/fMRI...............W102
Interleukin-6...............M13
internal capsule...............W136
international...............W129
internet...............M52, M100, W24
interneuron...............T177
Interoception...............T14, T121, W47
interpeduncular...............W252
interpretation bias...............T29
intracranial self-stimulation...............T183, T208, W108
Intranasal...............T93
Intranasal formulation...............T106
intravenous administration...............W224
ion channel...............M157
iPSC...............T126
Irritability...............M107, T29, T59
ITI-007...............W174
IV Alcohol...............T262
K
Kalirin...............1, M161
kappa agonist...............M129
kappa opioid receptor...............M104, M256, T247, W50, W62, W75, W255
KCa2 channels...............M245, W257
Ketamine...............M18, M61, M62, M73, M77, M160, M208, 22, T74, T91, T94, W78, W95, W108, W113, W114
kinases...............T65
Kynurenic acid...............T128, T131, 29
kynurenine...............T4, W195
L
Lactate...............W113
Large Scale Networks...............T34, W34, 56
Laser Capture...............W200
Late-life Depression...............T87, T113, T117
Lateral Habenula...............M79, T55, T73, W94, 59
Lateral Septum...............T235
Learning...............T136
learning and memory...............T49, T128, W107, W254
Leptin...............T20
lesion...............W144
leukocyte telomere length...............M85
levetiracetam...............W3
life stress...............M75
Linkage...............M118
lipid rafts...............W66
lipids...............M118
liquid chromatography/mass spectrometry...............M74
Lisdexamfetamine...............M46, M47
Lithium...............M143, W71
Lithium response...............M82
Locus coeruelus...............M33, W117
Locus coeruleus...............M209
long noncoding RNA...............M20, T52, W213
Long Term Potentiation...............T247
long-acting-antipsychotic...............T195
longitudinal...............M50, T234
LPS...............W81
LSD1...............W237
lurasidone...............M55, T92, W172, W203
Luzindole...............T109
M
Machine learning...............M108, T96, W36
MADRS...............W150
Magnetic Resonance Imaging...............W18
magnetic resonance spectroscopy...............M16, M208, T157, W44
Magnetic seizure therapy...............M68, W68
magnetization transfer...............M141
maintenance treatment...............M235, T112
Major depression...............M56, M63, M78, M80, M86, M92, 10, T58, T60, T83, T95, T98, T105, T107, T118, T121, W55, W72, W93, 46, 58
major depression history...............T103
major depression, post-traumatic stress disorder...............M95, W59
Major Depressive Disorder...............M55, M58, M68, M81, M89, M100, M111, M188, T74, W91
Major Depressive Disorder (MDD)...............M71, M117, T62, T69, T82, T100, T114, W61, W86
Major Psychiatric Disorders...............M202
mania...............W63, W71, W79, W192
marijuana...............T210, T244, T248
Maronutrient...............W258
mass spectrometry...............T198
Maternal...............M140
maternal separation...............T28
Matrix Metalloproteinase-9 (MMP-9)...............18
MCH...............M140
MDD...............M70, M88, M107, W113
MDPV...............M250
mecamylamine...............M136
Medial frontal cortex...............M31
Medial Prefrontal Cortex...............M11, M23, M33, M78, M182, M185, M2015, T99, T102, T182, T206, T255, T259, 36
Medication adherence...............W206
Medication Development...............T222
Medicinal Marijuana...............T249
mediodorsal thalamus...............W191
Medium Spiny Neuron...............M213, W228
Melatonin...............T109
memantine...............T151
Memory...............18, T3, T42, T111, T191
Memory and Learning...............M24, M214, T150, T260, W82
Memory Consolidation and Extinction...............T19
Memory Encoding and Retrieval...............M3, M119, W82
menopause...............M3, M4, M87
mental health service use...............M2
Mentoring...............M124, 26
meta-analysis...............W61, W93, W175
metabolic safety...............M156
metabolic syndrome...............T185, T201
metabolism...............T20
Metabolomics...............M128
metabotropic glutamate receptor...............M70, M123, T82, T159, T221, W173
metals...............W159
Methamphetamine...............M234, M263, T236, T239, T240, T241, W224, W249
Methionine...............T181
methods...............60
Methylphenidate...............T13, T24
mGlu2/3 receptor...............M77
mGlu5-PAM...............W4
mglur5...............W156
mGluR5 receptors...............M245
Mice...............M138, M202
microarray...............T197
Microdialysis...............M12, T207, W257, W261
microglia...............M64, 33
microglial activation...............W182
MicroRNA...............M102, T10, T124, T199
mild cognitive impairment due to AD...............M41
Mild Traumatic Brain Injury...............T140
minocycline...............T76
Minor Tobacco Alkaloids...............T237
Mismatch Negativity...............T152, T202, W198
missence mutations...............T163
Mitochondria...............T197, W185, W228
mitochondrial function...............W3
Mixed features...............T92
mobile health...............W206
Mobile phones...............M101
Mobile technology...............W105
moderators...............M253
molecular mechanisms...............M196, M209, T10, 50, 54
monkey...............M42, T252, W161
monkeys...............W244
Monoamine oxidase A...............M150, T116
monoamines...............T88, W83
Mood...............M66, T137
mood and addiction...............M246
mood and anxiety disorders...............M103, T84, W105
mood disorder...............M56, M116
mood disorders...............M109, T77, T89, T108, 30, W85
morphine...............M230, T225
morphological and resting state brain activity...............M237
motivated drug taking...............M231
motivation...............M125, M155, M238, T156, T212, W157, 21
motor stereotypies...............W33
mouse behavior...............M162, M230, W70, W196
mouse brain...............W194
mouse model...............T158, T185, T218, 45
Mouse models...............W170, W183
MPTP...............W138
MR spectroscopy...............M175, T100, T104, W163
MRI...............T25, M144, 16, T28, T41, T161
mRNA...............W252
MRS...............M22, M262, 12, W19
mTOR...............M230, W75
mu-opioid receptors...............M261, 58
multi-episode schizophrenia...............M166
Multiplex families...............T163
multivariate...............T189, W176
muscarinic acetylcholine receptor...............T65, W125, W173
myoinositol...............W19
N
N-acetylcysteine...............M241
Na+/H+ exchanger...............57
NAcore...............W257
NADPH oxidase...............M92
Naltrexone...............M254
national representative sample...............W230
national study...............W230
Native American...............W215
Native Americans...............M53
natural history genomic studies...............W169
negative emotionality...............W255
Negative Symptoms...............M155, M158, M204, W188
neural activity...............T188
neural circuitry...............23, T35, W80
neural circuits...............M119, M209, 14, 55
neural plasticity...............M189, T54
Neuregulin...............W138
Neuregulin-1...............W160
neuregulin-3...............T223
neuritogenesis...............M207
neuroactive steroid...............M74
neuroanatomy...............T36
neurobiology, stress, depression, anxiety, adolescence...............M14, M32, W96
neurochemistry...............T200
neurocircuitry...............M40, 43
neurocognition...............M189, T108, T154, T164, T175, W77, W189
neurodegeneration...............T141, W139
neurodegenerative...............T141
Neurodegenerative Disease...............M146
Neurodevelopment...............M146, M220, 34, 37, 42, W34, W130, 48
Neurodevelopmental Disorders...............T32, W149, W196
neuroeconomics...............W164
Neuroendocrine...............M63
Neuroendocrine system...............T246
neuroendocrinology...............T66
Neurofeedback...............47
Neurogenesis...............M138, T49, T109
neurogranin...............T160
Neuroimaging...............M150, T75, T96, T215, 34, W36, W55, W219, W226, 6
neuroimmune...............M117, W253
Neuroimmunology...............W204
Neuroinflammation...............M89, M110, M188, 12, T76, 40, T205, W81, W107
Neurological disorder...............M143
Neuromodulation...............T191, W121
Neuronal Epigenome...............W52
neurons...............T126, W181
neuropeptide Y...............M73
Neuropeptides...............W59
neurophysiological aspects of the origin of consciousness,...............T134
Neuropil...............W188
Neuroplasticity...............20, T211, W52, W210
Neuropsychiatric Adverse Events...............M244
neuropsychiatric inventory...............M145
neuropsychology...............T186, T196, T260
Neuroreceptor imaging...............T143, W45
neurosurgery...............W18
Neurotechnology...............W128
neuroticism...............M236
neurotransmitter co-release...............M125
new targets...............W90
nicotine...............M97, M136, M235, T129, T220, T243, T255, T257, W211, W235, W252
nicotine addiction...............T237, W238
Nicotine dependence...............M244, M249, T223, T248, W221
nicotinic acetylcholine receptors...............M97, M136, M162, T212, T248, W238
NIH...............8
nitric oxide...............T214, T251
nitric oxide donor...............M205
NMDA...............W199
NMDA Antagonists...............M18, M160, T49
NMDA channel blocker...............M212
NMDA glycine-site receptor...............M158, W245
NMDA Receptor...............1, M62, M186, M212, T153, W2, W185, W196, 29
NMDA Receptors...............T183, W167
non pharmacological interventions...............M100, 23, W205
non-linear...............M121
Non-Pharmacological Therapy...............M1, 45
Nonhuman Primate Models...............M75, T261
Nonhuman Primates...............M256, T237, W10, 56
norepinephrine...............T11
not just right experience...............M8
Notch...............M126
novel object recognition...............M214, W203
novel therapeutics...............T169, W70
NPSR1...............M16
Nucleus Accumbens...............M211, M213, T94, T214, T242, T253, W8, W13, W62, W84, W228, W234, 54
Nucleus Accumbens Shell...............T213, W236, W257
Nutrigenomics...............T48
O
Obesity...............T50, T58, T137, T246, 28, W8, W45, W46, W133, W134, W226
Obsessive Compulsive Disorder...............M22, 22, T125, T142, T143, W11, W18, W19, W29
Obsessive-Compulsive and Related Disorders...............M21
occupancy...............W152
OCD...............7, M8, M18, M22, T22, W9, 56
odor-related trauma...............M17
older adults...............M2
older patients...............W172
Olfaction...............M36
olfactory...............M17, M192
Omega-3 Fatty Acid...............M69, M82
open science...............W169
opioid...............M257, T228
Opioid dependence...............T217, W232
Opioid system...............4, T224
opioids...............M238, M258
OPRM1 A118G...............T224
optogenetics...............7, M76, M119, M137, M218, T19, T55, T158, T233, T259, W62, W117
Orbitofrontal cortex...............T238, W9
orexin...............W15
organic cation transporters...............T61, 57
oscillation...............M33
ovarian steriods...............M116
oxidative stress...............M22, M67, M194, T39
OXTR...............W146
oxytocin...............M122, M132, 24, T190, T226, T242, 27, W146, W164, W261
P
P300...............W193
p38 MAPK...............W50, W75
P50...............M25
PACAP...............T20, T115, T120, W59
Pain...............M142, M238
pair bond...............W131
Palatable food...............T49
paliperidone...............T195
paliperidone palmitate...............T187, W154
panic...............T14, W15
panic attacks...............M16
PANSS...............T204, W150
Parkinson's disease...............W138
Parkinsonism...............57
parvalbumin...............M31, T160, T197, W183, 53
parvalbumin interneurons...............M157, M169, T158, T199, W155, W234
pathological gambling...............M223
pathophysiology...............M178, M194, 30
Pavlovian...............M218
Pavlovian conditioning...............M242, W251
PDE2...............M92
PDE4...............M184, M228
pediatric...............T22, W32
penetrance...............W32
Perimenopause...............M113
perinatal...............W229
perinatal anxiety...............T103
perinatal depression...............T103
Peripheral Nerve Stimulation...............W121
personality...............W99, W122
PET...............2, M58, M70, M123, M144, M151, W156, M159, M226, T135, T150, T180, W174
PET Imaging...............M146, T140, W42, W123
PET study...............M227, 40
PFC...............W173
Pharmacodynamics...............W137
pharmacogenetic...............W15
Pharmacogenetics...............M59, M220, T127, T174, 60
Pharmacogenomics...............M195, W86, W87, W168, 48
Pharmacokinetics...............M34, T232
Pharmacology...............T56, T132, T169, 50
Pharmacotherapy...............M21, M239
phase of illness...............T193
phencyclideine...............W203
Phenotype Screening...............41
Phenotypes...............M201, W255
Phosphodiesterase-4 (PDE4)...............T42
Physical dependence...............M129
physical exercise...............M189
PKMzeta...............M225
Placebo Response...............W86
placebo-controlled trial...............M81
Polygenetic Risk Score...............M183, W1
polymorphism...............T124
POMC...............M126
population -based...............T194
positive allosteric modulators...............T206, W125
Positron Emission Tomography...............M54, M134, M216, T107, T143, T221, T248, W10, W60, W182
postmortem...............T198
Postmortem Brain Tissue...............M147, M196, M197, T43, T179, W42, W153, W200
postmortem human brain...............M207, W69
postpartum...............M140
Postpartum depression...............M74, T116, T66
posttraumatic stress...............M7, T23
Posttraumatic stress disorder...............M15, M26, M61, T12, T18, W88, 47
poverty...............M40
prairie voles...............W131
Precision Medicine for Depression...............M108
Preclinical...............M129
Preclinical Trial Methodology...............T1
precuneus...............T35
prediction...............19
Predictive Models...............T166, W189
Prefrntal cortex...............W149
prefrontal circuit...............W65
Prefrontal cortex...............M28, M96, M102, M162, M164, M165, M202, M221, T24, T28, T188, T207, T215, W2, W60, W217
prefrontal-amygdala-connectivity...............M32
Pregabalin...............W53
pregnancy...............M25, M74, T79, T232
prelimbic...............W214
premenstrual dysphoric disorder...............M116, T78
prenatal...............M44
prenatal smoking...............W29
prenatal stress...............M31, T40, 33
Prepulse Inhibition...............W187
Prescription drug abuse...............W230
prevalence...............W24
Prevention...............M112, T116, 45
Prevention of Alzheimer's disease...............M43, T1
primate model...............W22
probabilistic reasoning...............T192
Probabilistic reinforcement...............W161
Progesterone...............M113, T66, W246
propanolol...............T9
protein aggregation...............T184
Proteomics...............W200
proteostasis...............T184
Pseudobulbar affect...............T145
Psychiatric Comorbidity...............M103, M148
psychiatric disorders...............M194
psychiatric genetics...............M181, M229
psychiatry...............W136
psychoeducation...............W40
Psychoneuroimmunology...............M75, T100, W135
psychophysiology...............T15, T78
psychosis...............M174, M203, M212, T166, T186, T190, T204, W40, W162, W191
psychosis continuum...............W159
psychosis risk...............37
psychosocial stress...............W135
psychosomatic medicine...............W135
Psychostimulant...............T221, W261
Psychotherapy...............M9, M10, T12
psychotic disorders...............30
PTSD...............M6, M10, M17, M19, M23, M138, T8, T10, T15, 41, W17, W21, W23, W53, W74, W120, W147
pyramidal neuron...............M185
Q
QTG...............M229
QTL...............M219, M229
Quantitative Electroencephalography (qEEG)...............T209
R
R-fmri...............W63
Rabies tracing...............M217
Radiotracer...............M146
raloxifene...............M152
Raman spectroscopy...............T126
Randomised clinical trial...............M47
randomized clinical trial...............M100, W184
raphe...............T55
Rapid Antidepressant...............W57
rare variation...............W33, W201
Rat...............M46, M102, M129, T68, T238
rat strains...............M136
Rating scales...............W129
Reapprasial Training...............M149
reasons for change...............W215
recollection...............T193
Recovery...............W227
Recurrence risk...............W56
Redox modulation...............T39, 29
Regeneration...............W123
reinforcement...............T31
Reinforcement learning...............M155, T89, W161, W262
reinstatement...............M243, T235, W231
rejection...............W216
relapse...............M235, M240, M252, W214, W248
Relapse Prevention...............M21, T170, T195
relatives...............M199
Religion...............M127
repetitive behavior...............7
repetitive transcranial magnetic stimulation...............T112, 47
Replication...............8
Reproducibility...............8
reproduction...............T20
Research domain criteria (RDoC)...............M5, M7, M109, W158
Resilience...............M11, M87, M209, W52, W145
Resting state...............T18, T216
resting state fMRI...............T34, T69
Resting State Functional Connectivity...............M5, M14, M135, M236, T26, T36, T99, T101, T125, T149, T234, T239, T240, T243, W44, W85, W90, W101, W192, W197, W202, W209, W222, W235, W244, 46
Rett Syndrome...............T37
reversal learning...............T257
Reward...............M122, M254, M260, T47, T50, T94, T171, T238, W108, W161, W250, W251
reward neural circuitry...............M105, T46, W37, W90
reward pathwayd...............M238
reward prediction error...............W13, W262
reward processing...............M223, 21, T246, 36, 44
reward system...............M132, T33
Reward-based decision-making...............T257, W79, W157
RhoA...............T225
RiboTag...............W228
riluzole...............M86, M243
Risk...............M87, M131, T194, T217
risk taking behaviors...............M252
RNA binding protein...............M229
RNA Sequencing...............M116, T57, T127, W30, W42
RNA splicing...............T178
RNA-seq...............M96, T54, W10
ROC analysis...............M145
rTMS...............M30
S
S-glutathionylation...............M133
safety...............W172
Salience...............W117
salience network...............T18, W11, W222
Satiety...............M72
Schizophrenia...............1, M27, M147, M152, M153, M154, M156, M157, M158, M159, M161, M164, M167, M170, M171, M172, M173, M174, M179, M180, M181, M183, M188, M189, M191, M192, M193, M195, M197, M198, M199, M201, M204, M205, M206, M208, M235, T131, T151, T152, T153, T154, T156, T157, T158, T159, T160, T161, T162, T163, T164, T168, T169, T170, T171, T172, T177, T179, T181, T183, T184, T188, T189, T193, T194, T195, T196, T197, T199, T200, T202, T203, T204, 32, 39, 42, W152, W153, W156, W159, W160, W161, W162, W163, W164, W165, W169, W171, W172, W174, W176, W179, W180, W182, W186, W194, W195, W196, W204, 29, 50, 53
schizophrenia genetics...............M183, T192, W167, W175, W201
schizophrenia prodrome...............M163, W190, W198
Schizophrenia, Dopamine, Antipsychotics...............M151, M165, M168, M169, W166
schizophrenia, moderators...............T175
Schizophrenia-like Behavior...............M184, W170
schizotypy...............W167
Scopolamine...............T65, W58, W64
Scoring Accuracy...............W150
screening...............W199
seasonal affective disorder...............W60
selective estrogen receptor modulator...............M152
Self-Administration...............M221, M231, M234, M240, T237, T242, T261, W225, W231, 54
self-injury...............M38
Sensitive Period...............20, W35
sensitization...............T221, T255, W250
sensorimotor...............T45
sensory gating...............M184
sensory processing...............M8
septum...............M79
sequencing...............25, W148
Serious Mental Illness...............M200, W132
Serotonin...............M73, M77, M79, T72, 33, W5, W81, W116, W127, W178, W242
Serotonin 1b receptor...............M58, T53
serotonin 2A...............T182, T252
Serotonin 5-HT2C Receptor...............M134, W175
Serotonin 5-HT7...............W236
serotonin reuptake inhibitors...............T107
Serotonin Transporter...............M12, M60, T229, W60, W123
SERT...............W166
sex difference...............M69, M97, M109, 9, 34, W6, W241
Sex differences...............M12, M80, M251, T3, T6, T33, T60, W98, W118, W134, W219, W246
Sexual Dimorphism...............9, T98
sexual dysfunction...............T114
Sheehan Suicidality Tracking Scale...............M127
short-acting Kappa opioid receptor antagonist...............M104
sibling...............T194, W77
sign-tracking...............W126
Skin conductance response...............W118
skull shape...............W28
SLC6A4...............W14
sleep...............M114, M139, T34, T44, T128, T209, W110, W208
sleep disturbance...............M226, W16
sleep spindles...............T158, T191
Slitrk5...............22
slow waves...............T44
smartphone...............W206
Smoking...............M259, T210, W156, W229
Smoking Cessation...............T227, M244
Smoking urge...............M242, T226
SNP...............W167
sociability...............M36
Social...............T148, W247
Social Anxiety...............T7, W12
Social buffering...............W80
social cognition...............M203, M254, 24, T154, 36
Social Competence...............T176
Social defeat stress...............M33, M57, M61, M230, T81, T118, T233, W59, W80, W108
Social Functioning...............T111
social interaction...............T115, W216
social neuroscience...............M40, M122, T146
social recognition memory...............T190, T193
Social Rhythms...............M115
Social stimuli...............T228
social stress...............38, W38
social subordination...............W244
Source Localization...............M164
SPECT...............W152
Spice/K2 cannabinoids...............T250
spines...............T225
SSRI...............M186, T69, T80, T97, W93
startle latency...............M171
statistical methods...............T231, W111
stereotypy...............M38
stimulant...............T9
Stimulant Abuse...............W249
Stress...............M63, M64, M76, M94, M102, M249, T110, T120, W6, W22, W52, W94, W98, W214, 49
Stress circuits...............T67
stress response circuitry...............M109, 10
striatum...............M27, M262, T33, T69, T135, W63
Stroke...............T145
structural covariance...............T26
Structural MRI...............M24, M40, M181, M190, T41, T173, T189, 37
Subcallosal Cingulate...............W76, 59
Subclinical psychosis...............T41, T176, W190
subgenual...............T86, T99
Subjective Cognitive Impairment...............T1
subjective effects...............T129, T220, W224
Substance abuse...............M232, 17, T183
Substance use...............W154
substance use disorder...............5
Substance-related disorders...............T50, W233
subthalamic nucleus...............W209
Subtypes...............46
Suicide...............M83, M127, T5, T52, T56, W65, W69, W84
Suicide Assessment...............T27, W57
suicide behavior severity...............M93
sunshine act...............35
sustained attention...............T24
SV2A protein...............W3
synapses...............T43
synaptic connctions...............W155
Synaptic Plasticity...............M137, M245, 18, T223, T251, 28, W4, W143, W234, W250, 49
synaptic spine...............M205
Synthesis...............T72
systemic inflammation...............M110, W109, W135
systems biology...............3, 34
T
targeted cognitive training...............M180
task-based functional connectivity...............M17
tau...............T141
Technology...............M115
telemetry...............W208
Telomere...............W233
temperament...............W99
Test Retest...............M72
testosterone...............T11
Thalamus...............T74, W188
THC...............W7, W259
threat...............T17
Threat Conditioning...............W53
Threat of Shock...............T9, W23
thyroid...............T103
tianeptine...............58
timing...............W178
TMS...............M164, W102
Tobacco Smoking...............M247
Tolerability...............M193
Tolerance...............W221
Tourette syndrome...............7, T143, W29
toxoplasmosis...............M44
trace amine-associated receptor 1...............W231
Tractography...............M60, M106, W100, 59
Training...............M124, 26, T133
Trajectories...............W36
transcranial current stimulation...............T191
Transcranial Magnetic Stimulation...............T27, T107, T168, T211, W112, W260
transcription...............W183
transcription factor...............T165, W243
transcription factors...............10, W143
Transcriptomics...............3, T54, W143
transgenerational...............T40
transgenic mice...............M76, M185
TRANSGLUTAMINASE 2...............M84
translational imaging...............W260
Translational Neuroscience...............M135, T133
Transporters...............M130
Trauma exposure...............6, M5, W53, W109, W118, W120
trauma history...............T103
Traumatic Brain Injury...............T145
Traumatic stress...............M246
Treatment...............M224, M241, T217, 46, W78, W246
Treatment Outcome Prediction...............M78, M237, T1, T254
treatment refractory...............T82
Treatment resistance...............T203, W162
Treatment Resistant Depression...............M65, M103, T80, T85, T93, T97, T106, W100, W112, W114
treatment response...............M195, 27, W168, W175
TrkB...............M233, T102
trust...............W164
Tryptophan...............W141, W195
Tryptophan depletion...............T72
TSPO...............T140
TSPO and [11C]PBR-28 PET...............M89, M227, 12, W182
twins...............T200
type 2 diabetes mellitus...............M141, T83, W109
Type-2 Diabetes...............W46
U
UCSD Performance-Based Skills Assessment (UPSA)...............M71
ultra high-risk youth...............M163
Unconditioned responses...............W120
upregulation...............W227
uptake 2...............T61
User-centered design...............M101, T133
V
Vagus Nerve Stimulation...............W121
Varenicline...............M235, M253, T257
ventral hippocampus...............M19, M96, T16, T81
Ventral Striatum...............M182
Ventral Tegmental Area...............M209
Ventral tegmental area (VTA)...............M125, M217, M218, M230, T55, T247, W217, W262
ventrolateral prefrontal cortex...............T104, W38
Verbal Memory...............W82
vesicular glutamate transporter (VGLUT)...............M125
violence...............T149
Virtual Reality...............W157
vmPFC...............W238
voltammetry...............M232, M256, W58, W127
Vortioxetine...............M71, W83
voxel-based morphometry (VBM)...............T189, W18, W176
VTA...............W80
Vulnerability...............M231, 9, T21
W
wakefulness...............W208
wheel running...............W73
White Matter...............M106, M191, W194, W195
Whole exome sequencing...............M53, M116, W33, W201
williams syndrome...............W28
Withdrawal...............M249, M252, M257, T256, W31
women...............W219, W224
Women's Mental Health...............T79, W109
work readiness...............T187
working memory...............M42, M135, M198, M221, T165, T180, W2, W180, W187, W207
Working Memory Capacity...............T9
working memory fMRI...............W151, W171
X
xCT...............W220
Y
Yoga...............M1, T162
Z
zebrafish...............T132
ziprasidone...............M103
ΔFosB...............T81
Rights and permissions
About this article
Cite this article
Keyword Index. Neuropsychopharmacol 40 (Suppl 1), S656–S671 (2015). https://doi.org/10.1038/npp.2015.329
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2015.329